Skip to contentT
TELA Bio, Inc.
T
TELATELA Bio, Inc. Q2 2026 · 10-Q
Revenue$19.29M$19.29M−4.5% vs Q2 2025 Net Income-$11.26M-$11.26MN/M vs Q2 2025 EPS Diluted-$0.20-$0.20N/M vs Q2 2025 Gross Profit$13,943,000−1.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TELA Bio, Inc. · CIK 1561921 · Engraved from SEC EDGAR
Operating Cash Flowderived-$9,381,000N/M Free Cash Flowderived-$9,440,000N/M Margins · derivedGross margin72.3%+2.4 pt vs Q2 2025
Operating margin-48.1%−3.2 pt vs Q2 2025
Net margin-58.4%−9.2 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 11, 2026 · 42 d after period end